Related Experiment Videos
Rising PSA after a radical treatment
1Department of Urology, University of California San Francisco, San Francisco, CA 94143-0738, USA.
European Urology
|October 31, 2001
Summary
Biochemical recurrence after prostate cancer surgery is common. Analyzing prostate-specific antigen (PSA) levels and clinical factors helps determine treatment strategies for recurrent prostate cancer.
Area of Science:
- Urology
- Oncology
- Medical Diagnostics
Background:
- Radical prostatectomy is a primary treatment for localized prostate cancer.
- Despite surgical advancements, approximately 25% of patients experience biochemical recurrence.
- Biochemical recurrence, indicated by rising serum prostate-specific antigen (PSA), presents a significant clinical challenge.
Purpose of the Study:
- To review methods for assessing the likelihood of treatment failure after prostatectomy.
- To discuss the utility of PSA velocity and doubling time in distinguishing local vs. distant recurrence.
- To outline treatment options for recurrent prostate cancer based on recurrence patterns.
Main Methods:
- Analysis of clinical and pathological factors predictive of treatment failure.
- Evaluation of prostate-specific antigen (PSA) velocity and doubling time at biochemical recurrence.
- Review of treatment guidelines based on recurrence site (local vs. metastatic).
Main Results:
- Clinical and pathological factors can predict the probability of recurrence.
- PSA kinetics (velocity, doubling time) aid in localizing recurrent disease.
- Treatment decisions are stratified based on whether recurrence is local or distant.
Conclusions:
- Early prostate cancer detection and surgical techniques have improved, yet recurrence remains prevalent.
- PSA kinetics are crucial for guiding management of biochemical recurrence.
- Treatment options for recurrent prostate cancer include radiation therapy, systemic therapies (e.g., androgen deprivation), or surveillance.